Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus
Primary Purpose
Chronic Hepatitis B
Status
Unknown status
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Polyherbal
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Hepatitis B
Eligibility Criteria
Inclusion Criteria:
Adults aged above 18 years of age, with inactive chronic hepatitis B (HB) or immune tolerant phase, with or without dyslipidaemia and having all of the following
- HBsAg +ve for >6 months and anti-HBs negative
- Alanine amino transferase ≤ 2 upper limit of normal
- HBeAg positive or negative irrespective of viral DNA load
- Not currently on antiviral therapy for Chronic hepatitis B
Exclusion Criteria:
Any one of the following
- Patients with decompensated liver disease of any etiology(characterized by elevated bilirubin, raised International normalized ratio, or a history of ascites, variceal hemorrhage,hepatic encephalopathy, Spontaneous bacterial peritonitis, hepatorenal syndrome or Hepatocellular carcinoma)
- Family history of hepatocellular carcinoma
- Patients with HIV and Hepatitis C virus co-morbidity
- Pregnant, attempting to conceive, or lactating women
- Patients with diabetes mellitus
- Recent history of acute coronary syndrome (<6months) or chronic coronary artery disease with poor left ventricular function (by physician / cardiology opinion)
- Patients with renal failure ( Creatinine clearance less than 60 ml/min)
- Active substance or alcohol abuse and concurrent use of corticosteroids or immunosuppressive agents.
- Presence of extra hepatic manifestations
- Previously treated with pegylated interferon within the last 2 years
- Positive fibroscan or ultrasound elastography showing evidence of fibrosis (F3 and above)
- Current or former employees of organic India
- Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.
- Refusing consent or physician uncomfortable with patient compliance to treatments or follow up.
Sites / Locations
- Mazumdar Shaw Mutispeciality HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Polyherbal
Matching placebo
Arm Description
Combination of 3 whole herbs in a capsule
Similar looking inert capsules
Outcomes
Primary Outcome Measures
Number of patients with change in mean Hepatitis B Virus (HBV) DNA by at least 2log10 units from baseline at end of treatment for those with HBV DNA ≥ 1000 IU/ml.
Secondary Outcome Measures
Number of patients with change in hepatitis B surface antigen titers from baseline for those with HBV DNA <1000 IU/ml
Number of patients with Incidence of seroconversion from Hepatitis B surface antigen to anti-Hepatitis B surface antibody
Full Information
NCT ID
NCT02899130
First Posted
September 8, 2016
Last Updated
December 5, 2017
Sponsor
Composite Interceptive Med Science
1. Study Identification
Unique Protocol Identification Number
NCT02899130
Brief Title
Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus
Official Title
Antiviral Effect of 3 Herbs in Chronic Inactive Carriers of Hepatitis B Virus. - A Randomized Placebo Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Unknown status
Study Start Date
October 2016 (undefined)
Primary Completion Date
June 2018 (Anticipated)
Study Completion Date
September 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Composite Interceptive Med Science
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This trial will study the effect of a polyherbal capsule in lowering the viral load of patients with chronic Hepatitis B infection and record the incidence of from Hepatitis B surface antigen elimination in 12 months
Detailed Description
A placebo controlled randomised trial. 3 herbs that have proven effect on eliminating the virus and normalizing liver function will be given. Equally matched placebo (blinded) will be given randomly to patients. All parameters of hepatitis B infection will be compared between the randomized groups
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Hepatitis B
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Polyherbal
Arm Type
Experimental
Arm Description
Combination of 3 whole herbs in a capsule
Arm Title
Matching placebo
Arm Type
Placebo Comparator
Arm Description
Similar looking inert capsules
Intervention Type
Drug
Intervention Name(s)
Polyherbal
Other Intervention Name(s)
Liver Kidney Care
Intervention Description
Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Inactive compound that is similar looking as the intervention
Primary Outcome Measure Information:
Title
Number of patients with change in mean Hepatitis B Virus (HBV) DNA by at least 2log10 units from baseline at end of treatment for those with HBV DNA ≥ 1000 IU/ml.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Number of patients with change in hepatitis B surface antigen titers from baseline for those with HBV DNA <1000 IU/ml
Time Frame
12 months
Title
Number of patients with Incidence of seroconversion from Hepatitis B surface antigen to anti-Hepatitis B surface antibody
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults aged above 18 years of age, with inactive chronic hepatitis B (HB) or immune tolerant phase, with or without dyslipidaemia and having all of the following
HBsAg +ve for >6 months and anti-HBs negative
Alanine amino transferase ≤ 2 upper limit of normal
HBeAg positive or negative irrespective of viral DNA load
Not currently on antiviral therapy for Chronic hepatitis B
Exclusion Criteria:
Any one of the following
Patients with decompensated liver disease of any etiology(characterized by elevated bilirubin, raised International normalized ratio, or a history of ascites, variceal hemorrhage,hepatic encephalopathy, Spontaneous bacterial peritonitis, hepatorenal syndrome or Hepatocellular carcinoma)
Family history of hepatocellular carcinoma
Patients with HIV and Hepatitis C virus co-morbidity
Pregnant, attempting to conceive, or lactating women
Patients with diabetes mellitus
Recent history of acute coronary syndrome (<6months) or chronic coronary artery disease with poor left ventricular function (by physician / cardiology opinion)
Patients with renal failure ( Creatinine clearance less than 60 ml/min)
Active substance or alcohol abuse and concurrent use of corticosteroids or immunosuppressive agents.
Presence of extra hepatic manifestations
Previously treated with pegylated interferon within the last 2 years
Positive fibroscan or ultrasound elastography showing evidence of fibrosis (F3 and above)
Current or former employees of organic India
Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.
Refusing consent or physician uncomfortable with patient compliance to treatments or follow up.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alben Sigamani, MD
Phone
+91 8884431444
Email
alben.sigamani.dr@nhhospitals.org
First Name & Middle Initial & Last Name or Official Title & Degree
Sanjaya Chauhan, Pharm.D
Phone
+91 9611252350
Ext
2388
Email
drsanjayachauhan49@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alben Sigamani, MD
Organizational Affiliation
Narayana Hrudayalaya Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mazumdar Shaw Mutispeciality Hospital
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560099
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alben Sigamani, MD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus
We'll reach out to this number within 24 hrs